Health Care · Pharmaceutical Preparations

HURA TuHURA Biosciences, Inc./NV SEC Filings & Insider Trading Activity 2026

company
CIK 1498382129 filings
Russell 2000

HURA at a glance

TuHURA Biosciences, Inc./NV (HURA, SEC CIK 1498382) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 18, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), TuHURA Biosciences, Inc./NV (HURA) reported revenue of $0 and a net loss of $30.1 million. Diluted EPS was -$0.63.
  • As of September 30, 2026, 17 institutional investment managers tracked by SignalX reported holding TuHURA Biosciences, Inc./NV (HURA) shares worth $9.5 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$0
10-K XBRL
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
17 funds
$9.5M · +0 vs prior quarter
Latest 8-K
Nov 18, 2026
Item 2.03

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to previously disclosed risk factors since the 2025 Form 10-K
  • No newly added risk factor identified this quarter
  • Carried-forward risks remain those disclosed in the 2025 Form 10-K and March 31, 2026 Form 10-Q

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, with no products approved for sale
  • Net loss $6.4M vs $7.1M YoY, operating loss $5.7M vs $6.7M
  • Best program TBS-2025 R&D $0.4M, up $0.1M; IFx-2.0 $1.1M, down $0.5M
  • Cash $1.9M; operating cash use $18.1M, financing cash provided $16.5M
  • Runway into 2028 projected; additional funding needed, with clinical and development costs expected to increase substantially

AI summary of the HURA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 18, 2026Full analysis →

Item 2.03: Creation of a Direct Financial Obligation

  • $1.3 million borrowed through two $650,000 draws on the revolving credit facility
  • Borrowings intended for general corporate purposes, increasing near-term liquidity
Filed Nov 13, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results for the three months ended September 30, 2026
  • Corporate update accompanying the quarterly results

Item EX-99.1: Item EX-99.1

  • Q3 2026 results: cash $1.9M, with $9.2M drawn on Parkview’s credit facility
  • Parkview facility provided $5.6M during Q3, supporting operations without immediate equity dilution
Filed Nov 6, 2026Full analysis →

Item 2.03: Creation of a Direct Financial Obligation

  • Additional $1.5 million revolving-credit draw received November 2, 2026
  • Proceeds intended for general corporate purposes, supporting near-term liquidity

AI summaries of HURA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for HURA

Don't miss the next HURA filing

  • Alerts as it files. A push when HURA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut HURA, by share count.
  • Ask anything. An AI agent that reads every HURA filing and answers with sources.

HURA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Bianco James A.GNov 17, 2026-
Bianco James A.GMay 28, 2026-
List AlanAFeb 12, 2026-
Ng George KAFeb 12, 2026-
MANUSO JAMES S JAFeb 12, 2026-
Hoffman Robert E.AFeb 12, 2026-
Tendler CraigAFeb 12, 2026-
Bianco James A.AJan 6, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$0$0$0
Net Income-$29.3M-$21.7M-$30.1M
Balance Sheet
Total Assets$4.4M$20.0M$27.4M
Equity-$14.6M$20.9M
ROE--148.6%-143.6%
Per Share
EPS$-2.47$-1.21$-0.63
Cash Flow
Operating CF-$12.0M-$14.7M-$27.6M
CapEx$79K$58K$76K

Source: XBRL data in TuHURA Biosciences, Inc./NV (HURA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate HURA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
HURA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202617$9.5M
Q2 202617$14.9M
Q1 202619$12.0M
Q4 202518$3.8M
Q3 202517$11.4M
Q2 202517$10.8M
Q1 20258$8.0M
Q4 20246$3.9M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 119 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

HURA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 18, 2026Analysis-
4Nov 18, 2026--
8-KNov 13, 2026Analysis-
10-QNov 13, 2026Analysis
8-KNov 6, 2026Analysis-
8-KOct 16, 2026Analysis-
8-KSep 24, 2026Analysis-
8-KSep 17, 2026Analysis-
8-KSep 17, 2026Analysis-
8-KSep 16, 2026Analysis-
8-KSep 4, 2026Analysis-
8-KAug 21, 2026Analysis-
8-KAug 19, 2026Analysis-
8-KAug 14, 2026Analysis-
10-QAug 14, 2026Analysis
8-KAug 13, 2026--
8-KJul 29, 2026--
8-KJul 7, 2026--
8-KJun 17, 2026--
4May 29, 2026-
8-KMay 29, 2026-
8-KMay 15, 2026-
10-QMay 15, 2026Analysis
8-KApr 30, 2026--
8-KApr 22, 2026--

Related Health Care companies

All Health Care →

HURA SEC filings: frequently asked questions

Which institutions hold HURA stock?

As of September 30, 2026, the largest TuHURA Biosciences, Inc./NV (HURA) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($4.7 million), BlackRock ($1.2 million), Fifth Third Bancorp ($1.1 million), Millennium Management ($591,000), Bank of America Corp ($518,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What was HURA's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), TuHURA Biosciences, Inc./NV (HURA) reported revenue of $0 and a net loss of $30.1 million. Diluted EPS was -$0.63. The figures come from the XBRL data in the 10-K.

What did HURA report in its latest 8-K?

TuHURA Biosciences, Inc./NV (HURA) filed an 8-K on November 18, 2026 reporting Item 2.03 (Creation of a Direct Financial Obligation). $1.3 million borrowed through two $650,000 draws on the revolving credit facility.

What are the latest HURA SEC filings?

TuHURA Biosciences, Inc./NV (HURA) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 18, 2026 and a Form 4 insider filing on November 18, 2026.

What is HURA's SEC CIK number?

TuHURA Biosciences, Inc./NV (HURA)'s SEC Central Index Key (CIK) is 1498382. EDGAR lists every HURA filing under that number.

Ask anything about HURA

The research agent reads HURA's filings, financials, insider trades and 13F holders, then answers with sources.